CMG Pharmaceutical Completes Phase 1 Clinical Trial of Pan TRK Inhibitor Anticancer Drug
[Asia Economy Reporter Gong Byung-sun] CMG Pharmaceutical announced on the 31st that it has completed Phase 1 clinical trials of the Pan TRK inhibitor anticancer drug CHC2014 targeting long-term malignant solid tumors.
As a result of conducting clinical trials on 17 patients with long-term malignant solid tumors, it was found to be safe and well-tolerated. In addition, a dose-dependent pharmacokinetic profile was confirmed, and based on the overall safety results, the recommended dose for Phase 2 was also determined.
Hot Picks Today
Taking Annual Leave and Adding "Strike" to Profiles, "It Feels Like Samsung Has Collapsed"... Unsettled Internal Atmosphere
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- Blue House Protests Bloomberg's "Distorted Reporting on AI National Dividend"
- "After Vowing to Become No. 1 Globally, Sudden Policy Brake Puts Companies’ Massive Investments at Risk"
- On Teacher's Day, a Student's Gifted Cake Had to Be Cut into 32 Pieces... Why?
CMG Pharmaceutical expects that efficacy will also be demonstrated in the upcoming Phase 2 clinical trials.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
